Last updated: February 20, 2026
What does patent CA3205655 cover?
Patent CA3205655, titled "Method of treating multiple sclerosis with sphingosine-1-phosphate receptor modulators," is assigned to Novartis AG. Filed on February 22, 2013, it was granted on September 8, 2020. The patent's priority date is February 22, 2012.
Core invention
The patent claims a method of treating multiple sclerosis (MS) utilizing sphingosine-1-phosphate receptor (S1PR) modulators, particularly fingolimod (marketed as Gilenya). It specifies treatment regimes that include administering certain S1PR modulators, with claims emphasizing their use in controlling disease progression and relapse rates.
Claims overview
-
Method Claims: Focus on administering a therapeutically effective amount of S1PR modulators to treat MS, especially relapsing-remitting MS (RRMS). Claims include specific dosing regimens, administration routes, and formulations.
-
Composition Claims: Cover pharmaceutical compositions comprising fingolimod or related S1PR modulators in combination with excipients suitable for oral administration.
-
Use Claims: Encompass the use of these modulators in manufacturing medicaments for MS treatment.
Key claim elements:
- Administration of S1PR modulators such as fingolimod.
- Focus on relapse reduction, delaying disability progression.
- Dosing ranges notably include 0.5 mg to 1.25 mg daily.
The claims are broad, covering methods of use and compositions, with some dependent claims narrowing the scope to specific dosage regimens and treatment durations.
Patent landscape: Related patents and filings
Patent families and key competitors
-
Novartis: Holds the primary patent (CA3205655) and related patents covering fingolimod formulations, methods of use, and specific dosing regimens.
-
Other S1PR Modulator Patents: Several patents cover alternative S1PR receptor modulators, including Kowa's KRP-203 and other derivatives, often focusing on selectivity and alternative delivery routes.
-
Patent expiration: CA3205655 is set to expire in 2033, considering the usual patent lifespan from the grant date and potential extensions.
Key jurisdictions for these patents
-
United States: Similar patents filed, with parallel patent families (e.g., US #######).
-
Europe: Supplementary protection certificates (SPCs) extend exclusivity until approximately 2035.
-
Japan and other jurisdictions: Patent counterparts exist, especially in markets with high MS prevalence.
The patent landscape for S1PR modulators in MS therapy is dense, with multiple filings competing over specific compounds, formulations, and methods.
Patent challenges and freedom-to-operate considerations
-
Existing patents on fingolimod's use and formulations create barriers for generic entry until patent expiry or licensing.
-
Some patents may face validity challenges based on prior art references related to early S1PR receptor research.
Impact on market and innovation
The broad claims of CA3205655 secure Novartis’s market exclusivity for key MS treatment methods using fingolimod. The patent's scope blocks similar S1PR modulators with comparable dosing regimes in the Canadian market until expiration. Independent competitors have pursued alternative receptor targets or delivery methods to circumvent these patents.
Regulatory and legal considerations
-
Patent protection enables Novartis to maintain market DS exclusivity, thus protecting revenue streams from Gilenya.
-
Clinical pipeline advancements involve next-generation S1PR modulators with potentially broader or narrower claims to extend patent life or circumvent existing patents.
Summary
| Aspect |
Details |
| Patent number |
CA3205655 |
| Filing date |
February 22, 2013 |
| Grant date |
September 8, 2020 |
| Expiry |
September 8, 2033 (likely, subject to potential extensions or legal challenges) |
| Invention scope |
Method of treating MS with S1PR modulators, especially fingolimod |
| Key claims |
Dosing, composition, therapeutic application |
| Main competitors |
Kowa, Biogen, Merck (alternative MS treatments and receptor modulators) |
| Geographic scope |
Canada, with related patents in US, Europe, Japan |
Key Takeaways
- CA3205655 provides broad protection for treating MS using fingolimod with specific dosing strategies.
- The patent landscape remains active with multiple filings aimed at different receptor modulators and formulations.
- Patent expiry targeted for 2033, after which generic competition in Canada is expected.
- Legal disputes could influence patent longevity or scope, particularly in jurisdictions with differing patent laws.
- Innovation continues with efforts to develop next-generation S1PR modulators to customize selectivity and reduce adverse effects.
FAQs
1. Does patent CA3205655 cover all S1PR modulators?
No. It specifically claims fingolimod and structurally related compounds. Other modulators with different structures are not covered unless explicitly included in claims.
2. Can a generic manufacturer produce MS treatments based on fingolimod after 2033?
Yes, after patent expiration, generic manufacturers may seek approval without infringing on these patents, subject to regulatory review.
3. Are there ongoing patent filings related to CA3205655?
Yes, related patent applications exist globally, including continuation and divisionals that aim to extend protection or cover new formulations.
4. How does this patent influence clinical development?
It constrains development of fingolimod-based therapies until patent expiry unless licensing agreements are secured.
5. What are the legal risks for competitors?
Possible patent infringement lawsuits or challenges based on prior art or claim breadth, especially if attempting to modify formulations or dosing strategies.
References
[1] Canadian Intellectual Property Office. Patent CA3205655, "Method of treating multiple sclerosis with sphingosine-1-phosphate receptor modulators," 2013.
[2] Novartis AG. Patent family filings and related patents, 2013–2022.
[3] European Patent Office. Supplementary Protection Certificates for fingolimod, 2020–2022.
[4] U.S. Patent and Trademark Office. Parallel patent filings covering fingolimod methods of use.
[5] MS treatment patent landscape analysis, 2022.
